Next week, Paul Evans will join the panel discussion on if the consolidation of independent clinical trial sites into larger, integrated networks will bring new researchers and new locations into clinical research, as well as lead to reduced risk to sponsors, increased predictability, streamlined site operations and greater access for patients at #DPHARM2024. If you’ll be in #Philadelphia for the DPHARM Conference next week, be sure to attend the panel, hosted by Mark Travers of Merck. #SiteNetworks #ClinicalResearch
Velocity Clinical Research, Inc.
Biotechnology Research
Durham, North Carolina 22,908 followers
Delivering high-quality clinical trial data and patient care with unprecedented efficiency.
Über uns
Velocity is the world’s leading organization of fully integrated clinical research sites. With 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
- Website
-
https://velocityclinical.com
External link for Velocity Clinical Research, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Durham, North Carolina
- Typ
- In Privatbesitz
- Gegründet
- 2018
- Spezialitäten
- Clinical trials, Patient Recruitment, Vaccine Research, Pharmaceutical Research, Clinical Research, Vaccines, Neurology, Pediatrics, NASH, Infectious Disease, Dermatology, Women's Health, Gastroenterology, Alllergy, Medical Devices, Research Sites, Principal Investigators, and Drug Development
Standorte
Employees at Velocity Clinical Research, Inc.
Aktualisierungen
-
Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina's clinical research industry. As Paul notes, "Our industry is in the same place as most people with AI. We've seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on to how you use AI to transform the industry." Under Paul's leadership — and with a technology hub in Hyderabad, India — Velocity Clinical Research continues to be at the forefront of innovation, navigating the complexities of AI integration while maintaining a rapid growth trajectory. With 90 sites across the U.S., U.K., Germany, and Poland, and a database of over 1 million patients, Velocity is poised to leverage AI for future advancements in clinical trials. Read the full article: https://lnkd.in/gEBxhvHt
-
We’re excited to announce that Velocity’s VISION Engage app has surpassed 100,000 downloads worldwide! This marks a step forward in our mission to revolutionize clinical trial accessibility through advanced technology and AI. With VISION Engage, participants can easily self-screen, self-schedule, and manage their trial experience — all from their mobile devices on their own time. Thank you to everyone who has downloaded and trusted VISION Engage. Together, we’re shaping the future of clinical research. Learn more about VISION technology: https://lnkd.in/gpZECMhS #ClinicalTrials #AI #HealthTech #Innovation #VISIONEngage
-
Popular weight loss drugs like Wegovy and Ozempic (semaglutide) may have another big benefit — reducing the risk of death from COVID-19. Making headlines over the weekend, an analysis of the large Novo Nordisk Phase 3 SELECT trial, supported by Velocity sites in the U.S., Germany, and Poland, found that injections of semaglutide reduced the risk of deaths from COVID-19 infection by about a third, in addition to cutting the risk of death from cardiovascular disease. We're proud to have researched this drug, and look forward to further studying its potential benefits. Read more: https://lnkd.in/daKF-EHR Read the full study results, published in the Journal of American College of Cardiology (JACC): https://lnkd.in/gAPNb3Zr
-
For a third year, we have topped Business North Carolina’s Fast 40 List of fast-growing middle market businesses in the state. This annual list recognizes companies headquartered in North Carolina that demonstrate exceptional entrepreneurial spirit, innovative business strategies, and outstanding revenue growth. Paul Evans, President & CEO, accepted the award this past week, less than a year after receiving CEO of the Year by the same publication.
-
As we start September, Laura Falcone, APRN, reflects on navigating the new realities of vaccine season. After Operation Warp Speed, we've seen increased protocol complexity, shorter enrollment windows, and a greater focus on diversity and reaching distinct cohorts. Read The Recap to learn how Velocity is leveraging innovative approaches — particularly in patient recruitment and retention — to drive more effective trial delivery. #ClinicalTrials #Vaccines
The Recap: September 2024
Velocity Clinical Research, Inc. on LinkedIn
-
Brandon Essink, MD, CPI, and J. Scott Overcash, M.D., were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.” From the article: “Boosting elicited greater immune responses against SARS-CoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with mRNA-1273 demonstrated acceptable safety, effectiveness and immunogenicity against COVID-19, including emergent variants.” Congratulations to Moderna, the patients, and all Velocity sites that supported this research program! Link: https://lnkd.in/g8qd2VC9 #Vaccines #COVID
-
The Society for Clinical Research Sites (SCRS) Site Solutions Summit is one month away! Meet our team in Hollywood, Florida at Booths 100 and 101 to test your skills and learn how Velocity is bringing much needed improvements to the clinical research process. Be sure to attend presentations and panels on Saturday, September 28 featuring Paul Evans, Stephanie Anderson, MA, SHRM-CP, and Rick Fisher. Scroll through the images below to learn more. Also attending: Craig Koch, Nicholas Campbell, Dan Robitaille, Jennifer Carl, Christy Godwin, Paul Kergides, Grant Miller, and Brittany Weichers
-
Here's a great example of what community outreach can do to improve lives, even beyond the clinic. Our Durham site currently has elementary teachers enrolled in clinical trials. During a recent visit, they were discussing the need for books in their classrooms with Joseph Henderson, our community liaison in Durham. After Joseph talked to a few of his connections, 150 brand new books arrived at the clinic for us to donate. Half will go to a local school, and the other half will go to a local homeless shelter or family crisis shelter. #CommunityOutreach #ClinicalResearch
-
Congratulations to Pfizer and Moderna on receiving EUA on their updated mRNA COVID-19 vaccines. We would also like to congratulate and thank all sites, patients, and investigators who continue to support COVID-19 research.
Today, we approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. https://lnkd.in/ecdYWGQr The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death.